Goldman Sachs analyst Nathan Rich downgraded Align Technology to Sell from Neutral with a $197 price target. In a weaker macro environment, the firm sees clear aligners and implants as most exposed to potential trade downs and delayed purchases and for Align it also sees increased competitive challenges in the general practitioner and ortho channels. In addition, the firm believes Align’s growth is more meaningfully lagging AngelAlign in China.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALGN:
- SmileDirectClub begins ‘swift wind down of business to maximize value’
- SmileDirectClub likely to liquidate as rescue bid fails, Bloomberg reports
- Early notable gainers among liquid option names on November 20th
- At Multi-Year Lows, Is Align Technology Stock (NASDAQ:ALGN) a Buy?
- Fly Insider: Barnes Group, Palo Alto among week’s notable insider trades
